The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Join the Hive!

the European Sting Milestones

Featured Stings

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

What you need to know about the Sustainable Development Impact Summit

The Franco-German axis considers that all EU needs now is more armaments

Banks launch green charter to help shipping reduce its carbon footprint

‘Virginity testing’: a human rights violation, with no scientific basis – UN

Myanmar military target civilians in deadly helicopter attack, UN rights office issues war crimes warning

Eliminating waste at scale – eight opportunities for blockchain

A Young entrepreneur cries out: “start in Europe, stay in Europe”

On Kristallnacht anniversary, UN chief urges renewed fight against ‘crime’ of anti-Semitism

Rule of Law: European Commission takes new step to protect judges in Poland against political control

Siemens-Alstom merger: Will the EC succumb to Franco-German pressures for the sake of May’s EU Elections?

IFMSA and IPSF on the Health of Migrants and Refugees

Brexit: Only Corbyn and May in concert can make the needed compromises

Three ways China can make the New Silk Road sustainable

Antitrust: Commission fines Sanrio €6.2 million for restricting cross-border sales of merchandising products featuring Hello Kitty characters

IMF cuts global growth outlook, but predicts pick up later in 2019

Good Governance in developing modern quality infrastructure systems

Greater support needed for refugees and migrants from Venezuela – UN

Saudi Arabia must halt air strikes in Yemen, says UN panel

Why is the World Health Organisation so much needed?

Amidst ‘high political tension’, UN chief appeals to G20 leaders for stronger commitment to climate action, economic cooperation

China in my eyes

China is building 8 new airports a year

Greening the Belt and Road is essential to our climate’s future

Europe’s top court hears Intel and sends € 1.06 bn antitrust fine to review

CLIMATE CHANGE FOCUS: Tunisia coastline in need of climate cash boost

The US + Britain trivialize mainland Europe, NATO and the EU

Can Europe and the US reverse their nationalist and xenophobic drift? Is the West becoming belligerent?

Why Indian students are going abroad to become Doctors?

We can make sure Globalization 4.0 leaves no one behind. This is how

Nuclear weapons in Lithuania: defence against Russia or target for terrorists?

Is a full course lunch, a new Commissioner and 2 million anti-TTIP citizens what you would call a “Fresh Start”?

FROM THE FIELD: Keeping Morocco’s indigenous culture and conservation in balance

Council strongly criticised over failing to act to protect EU values in Hungary

Air pollution, the ‘silent killer’ that claims seven million lives a year: rights council hears

Mother of all mergers between Facebook Messenger, WhatsApp and Instagram: EU Data Privacy restrictions against Facebook’s imperialistic plans

ILO: Unemployment to increase by 8.1 million in 2013-2014

These countries are all building brand-new cities

‘Virtual Biopsy’ device detects skin tumours in 15 minutes

Heat stress spike predicted to cost global economy $2,400 billion a year

Is the EU’s enlargement over-stretched?

Foreign investment to be screened to protect EU countries’ strategic interests

Globalization 4.0 will help us tackle climate change. Here’s how

After Brexit and Grexit, Brussels to deal with Poloust

Over 820 million people suffering from hunger; new UN report reveals stubborn realities of ‘immense’ global challenge

How we can embrace the electrical vehicle transition by adopting smart charging

‘Health is a right, not a privilege’ says WHO chief on World Health Day

A record one million Syrians displaced over six months, during six key battles: UN investigators

Commission’s report shows that targeted investment and robust digital policies boost Member States’ performance

‘Refrain from violence’ UN chief urges, as presidential election result is announced in DR Congo

The inhumane face of crisis mirrored in numbers

The future of manufacturing is smart, secure and stable

A Sting Exclusive: “Doing ourselves a favour”, Vice President Dombrovskis underscores that this time growth has to come from within the EU

My experience living with depression and schizophrenia in Thailand

Working Muslim women are a trillion-dollar market

How we overhauled healthcare amid Venezuela’s crisis

Commission makes it easier for citizens to access health data securely across borders

Congrats to the #FutureofMalta: a new age of voting

NATO summit, Brussels, 11-12/07/2018

Obama turns the G20 summit into warmongering platform

As human genome editing moves from the lab to the clinic, the ethical debate is no longer hypothetical

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s